市場調查報告書
商品編碼
1053746

腫瘤/癌症治療藥的全球市場的成長機會、產業預測 (2021-2030年):各藥物類別類型 (化療、標靶治療、免疫療法、荷爾蒙療法)、適應症

Oncology/Cancer Drugs Market By Drug Class Type (Chemotherapy, Targeted Therapy, Immunotherapy, and Hormonal Therapy), By Indication : Opportunity Analysis and Industry Forecast, 2021-2030

出版日期: | 出版商: Allied Market Research | 英文 252 Pages | 商品交期: 2-3個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

全球腫瘤/癌症治療藥的市場規模,2020年為1,354億9,417萬美元,從2021年到2030年預計以7.5%的年複合成長率發展,2030年成長到2,744億63萬美元的規模。

各種類型的癌症治療中,單株抗體(mAb)為基礎的生物藥品成為有利的選項。癌症的發生率上升,先進治療方法(生物學性治療方法和標靶藥物治療方法)的普及,全球老年人增加等成為促進該市場成長的主要原因。還有癌症的認識高漲,癌症的早期發現,抗癌藥的取得容易度等也促進市場成長。再加上新興國家的潛在性高,及開發平台數多對進入經營者顯示新機會。同時,新藥的開發的高成本,及對抗癌藥治療伴隨的失敗和副作用的畏懼抑制市場成長。

本報告提供全球腫瘤/癌症治療藥的市場調查,市場定義和概要,市場影響因素的分析,臨床試驗趨勢,市場規模的變化、預測,藥物類別類型、適應症、地區/主要國家等各種區分的明細,競爭環境,主要企業簡介等彙整資訊。

目錄

第1章 簡介

第2章 摘要整理

第3章 市場概要

  • 市場定義和範圍
  • 主要調查結果
  • 主要企業的地位
  • 波特的五力分析
  • 臨床試驗
  • 市場動態
    • 促進因素
    • 阻礙因素
    • 市場機會
    • 影響分析
  • COVID-19:影響分析

第4章 腫瘤/癌症治療藥市場:各藥物類別類型

  • 概要
  • 化療
  • 標靶治療
  • 免疫療法
  • 荷爾蒙療法
    • 主要市場趨勢、成長要素、機會
    • 市場規模、預測
    • 市場分析:各國

第5章 腫瘤/癌症治療藥市場:各適應症

  • 概要
  • 肺癌
  • 胃癌
  • 大腸癌
  • 乳癌
  • 前列腺癌
  • 肝癌
  • 食道癌
  • 子宮頸癌
  • 腎臟癌
  • 膀胱癌
  • 其他
    • 市場規模、預測:各地區
    • 市場分析:各國

第6章 腫瘤/癌症治療藥市場:各地區

  • 概要
  • 北美
  • 歐洲
  • 亞太地區
  • 南美、中東、非洲

第7章 企業簡介

  • ABBVIE INC.
  • AMGEN, INC.
  • ASTELLAS PHARMA INC.
  • ASTRAZENECA PLC
  • BRISTOL-MYERS SQUIBB COMPANY
  • F. HOFFMANN-LA ROCHE AG
  • JOHNSON & JOHNSON
  • MERCK & CO., INC.
  • NOVARTIS INTERNATIONAL AG
  • PFIZER, INC.
目錄
Product Code: A00042

The global oncology/cancer drugs market was valued at $135,494.17 million in 2020, and is projected to reach $274,400.63 million by 2030, registering a CAGR of 7.5% from 2021 to 2030.

Cancer is the uncontrolled growth of abnormal cells in the body. Cancer develops when the body's normal control mechanism stops working. Old cells do not die and instead grow out of control, forming new, abnormal cells. The treatment of cancer in patients requires the use of different drugs like hormonal therapy, immunotherapy, targeted therapy, and chemotherapy.

Biological drugs based on monoclonal antibodies (mAbs) have emerged as a preferred option to treat various cancer types. Rise in incidence of various cancer conditions, increase in popularity of advance therapies (biological and targeted drug therapies), and surge in geriatric population worldwide are the key factors driving the growth of the global oncology/cancer drugs market. Furthermore, rise in cancer awareness, early screening of the cancer and availability of cancer drugs are expected to boost the market growth.

However, high cost involved in new drug development coupled with threat of failure & adverse effects associated with cancer drugs therapies is expected to restrain the growth of the market. Conversely, high potential of emerging economies and higher number of potential drugs in pipeline are expected to provide new opportunities for market players in future.

The global oncology/cancer drugs market is segmented based on drug class type, indication, and region. Depending on drug class type, the market is divided into chemotherapy, targeted therapy, immunotherapy (biologic therapy), and hormonal therapy. By indication, it is categorized into lung cancer, stomach cancer, colorectal cancer, breast cancer, prostate cancer, liver cancer, esophagus cancer, cervical cancer, kidney cancer, bladder cancer, and other cancers.

Region wise, the market is studied across North America (U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA). The major companies profiled in the report include AbbVie Inc., Amgen, Astellas Pharma Inc., AstraZeneca PLC, Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Johnson & Johnson (Janssen Global Services, LLC,), Merck & Co., Inc., Novartis AG, and Pfizer Inc.

KEY BENEFITS FOR STAKEHOLDERS

  • This report provides a detailed quantitative analysis of the current market trends and future estimations from 2020 to 2030, which assists to identify the prevailing market opportunities.
  • An in-depth analysis of various regions is anticipated to provide a detailed understanding of the current trends to enable stakeholders to formulate region-specific plans.
  • A comprehensive analysis of the factors that drive and restrain the growth of the oncology/cancer drugs market is provided.
  • An extensive analysis of various regions provides insights that allow companies to strategically plan their business moves.

KEY MARKET SEGMENTS

BY DRUG CLASS TYPE

  • Chemotherapy
  • Targeted Therapy
  • Immunotherapy (Biologic Therapy)
  • Hormonal Therapy

BY INDICATION

  • Lung Cancer
  • Stomach Cancer
  • Colorectal Cancer
  • Breast Cancer
  • Prostate Cancer
  • Liver Cancer
  • Esophagus Cancer
  • Cervical Cancer
  • Kidney Cancer
  • Bladder Cancer
  • Other Cancers

By REGION

  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
  • Asia Pacific
  • Japan
  • China
  • Australia
  • India
  • South Korea
  • Rest of Asia Pacific
  • LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA

KEY MARKET PLAYERS

  • AbbVie Inc.
  • Amgen
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche Ltd.
  • Johnson & Johnson (Janssen Global Services, LLC,)
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

  • 1.1.Report description
  • 1.2.Key benefits for stakeholders
  • 1.3.Key market segments
    • 1.3.1.List of key players profiled in the report
  • 1.4.Research methodology
    • 1.4.1.Secondary research
    • 1.4.2.Primary research
    • 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

  • 2.1.Key findings of the study
  • 2.2.CXO perspective

CHAPTER 3:MARKET OVERVIEW

  • 3.1.Market definition and scope
  • 3.2.Key findings
    • 3.2.1.Top investment pockets
    • 3.2.2.Top winning strategies
  • 3.3.Top player positioning, 2020
  • 3.4.Porter's five force analysis
  • 3.5.Clinical trials
  • 3.6.Market dynamics
    • 3.6.1.Drivers
      • 3.6.1.1.Rise in incidence of cancer across the globe
      • 3.6.1.2.Surge in the global geriatric population
      • 3.6.1.3.Increase in government expenditure on healthcare
    • 3.6.2.Restraint
      • 3.6.2.1.Adverse effect associated with the use cancer drugs
    • 3.6.3.Opportunities
      • 3.6.3.1.High growth potential in untapped emerging economies
      • 3.6.3.2.Increase in number of pipeline drugs
    • 3.6.4.Impact analysis
  • 3.7.COVID-19 Impact Analysis on Oncology/cancer Drugs Market

CHAPTER 4:ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE

  • 4.1.Overview
    • 4.1.1.Market size and forecast
  • 4.2.Chemotherapy
    • 4.2.1.Key market trends, growth factors, and opportunities
    • 4.2.2.Market size and forecast, by region
    • 4.2.3.Market analysis, by country
  • 4.3.Targeted therapy
    • 4.3.1.Key market trends, growth factors, and opportunities
    • 4.3.2.Market size and forecast
    • 4.3.3.Market analysis, by country
  • 4.4.Immunotherapy
    • 4.4.1.Key market trends, growth factors, and opportunities
    • 4.4.2.Market size and forecast
    • 4.4.3.Market analysis, by country
  • 4.5.Hormonal therapy
    • 4.5.1.Key market trends, growth factors, and opportunities
    • 4.5.2.Market size and forecast
    • 4.5.3.Market analysis, by country

CHAPTER 5:ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION

  • 5.1.Overview
    • 5.1.1.Market size and forecast
  • 5.2.Lung Cancer
    • 5.2.1.Market size and forecast, by region
    • 5.2.2.Market analysis, by country
  • 5.3.Stomach Cancer
    • 5.3.1.Market size and forecast, by region
    • 5.3.2.Market analysis, by country
  • 5.4.Colorectal Cancer
    • 5.4.1.Market size and forecast, by region
    • 5.4.2.Market analysis, by country
  • 5.5.Breast Cancer
    • 5.5.1.Market size and forecast, by region
    • 5.5.2.Market analysis, by country
  • 5.6.Prostate Cancer
    • 5.6.1.Market size and forecast, by region
    • 5.6.2.Market analysis, by country
  • 5.7.Liver Cancer
    • 5.7.1.Market size and forecast, by region
    • 5.7.2.Market analysis, by country
  • 5.8.Esophageal cancer
    • 5.8.1.Market size and forecast, by region
    • 5.8.2.Market analysis, by country
  • 5.9.Cervical Cancer
    • 5.9.1.Market size and forecast, by region
    • 5.9.2.Market analysis, by country
  • 5.10.Kidney Cancer
    • 5.10.1.Market size and forecast, by region
    • 5.10.2.Market analysis, by country
  • 5.11.Bladder Cancer
    • 5.11.1.Market size and forecast, by region
    • 5.11.2.Market analysis, by country
  • 5.12.Other Cancers
    • 5.12.1.Market size and forecast, by region
    • 5.12.2.Market analysis, by country

CHAPTER 6:ONCOLOGY/CANCER DRUGS MARKET, BY REGION

  • 6.1.Overview
    • 6.1.1.Market size and forecast
  • 6.2.North America
    • 6.2.1.Key market trends, growth factors, and opportunities
      • 6.2.2.1.U.S.
      • 6.2.2.1.1.U.S. Oncology/cancer drugs market, by drug class type
      • 6.2.2.1.2.U.S. Oncology/cancer drugs market, By indication
      • 6.2.2.2.Canada
      • 6.2.2.2.1.Canada Oncology/cancer drugs market, by drug class type
      • 6.2.2.2.2.Canada Oncology/cancer drugs market, By indication
      • 6.2.2.3.Mexico
      • 6.2.2.3.1.Mexico Oncology/cancer drugs market, by drug class type
      • 6.2.2.3.2.Mexico Oncology/cancer drugs market, By indication
    • 6.2.3.North America market size and forecast, by drug class type
    • 6.2.4.North America market size and forecast, By indication
  • 6.3.Europe
    • 6.3.1.Key market trends, growth factors, and opportunities
    • 6.3.2.Market size and forecast, by country
      • 6.3.2.1.Germany
      • 6.3.2.1.1.Germany Oncology/cancer drugs market, by drug class type
      • 6.3.2.1.2.Germany Oncology/cancer drugs market, By indication
      • 6.3.2.2.France
      • 6.3.2.2.1.France Oncology/cancer drugs market, by drug class type
      • 6.3.2.2.2.France Oncology/cancer drugs market, By indication
      • 6.3.2.3.UK
      • 6.3.2.3.1.UK Oncology/cancer drugs market, by drug class type
      • 6.3.2.3.2.UK Oncology/cancer drugs market, By indication
      • 6.3.2.4.Italy
      • 6.3.2.4.1.Italy Oncology/cancer drugs market, by drug class type
      • 6.3.2.4.2.Italy Oncology/cancer drugs market, By indication
      • 6.3.2.5.Spain
      • 6.3.2.5.1.Spain Oncology/cancer drugs market, by drug class type
      • 6.3.2.5.2.Spain Oncology/cancer drugs market, By indication
      • 6.3.2.6.Rest of Europe
      • 6.3.2.6.1.Rest of Europe Oncology/cancer drugs market, by drug class type
      • 6.3.2.6.2.Rest of Europe Oncology/cancer drugs market, By indication
    • 6.3.3.Europe market size and forecast, by drug class type
    • 6.3.4.Europe market size and forecast, By indication
  • 6.4.Asia-Pacific
    • 6.4.1.Key market trends, growth factors, and opportunities
    • 6.4.2.Market size and forecast, by country
      • 6.4.2.1.Japan
      • 6.4.2.1.1.Japan Oncology/cancer drugs market, by drug class type
      • 6.4.2.1.2.Japan Oncology/cancer drugs market, By indication
      • 6.4.2.2.China
      • 6.4.2.2.1.China Oncology/cancer drugs market, by drug class type
      • 6.4.2.2.2.China Oncology/cancer drugs market, By indication
      • 6.4.2.3.Australia
      • 6.4.2.3.1.Australia Oncology/cancer drugs market, by drug class type
      • 6.4.2.3.2.Australia Oncology/cancer drugs market, By indication
      • 6.4.2.4.India
      • 6.4.2.4.1.India Oncology/cancer drugs market, by drug class type
      • 6.4.2.4.2.India Oncology/cancer drugs market, By indication
      • 6.4.2.5.South Korea
      • 6.4.2.5.1.South Korea Oncology/cancer drugs market, by drug class type
      • 6.4.2.5.2.South Korea Oncology/cancer drugs market, By indication
      • 6.4.2.6.Rest of Asia-Pacific
      • 6.4.2.6.1.Rest of Asia-Pacific Oncology/cancer drugs market, by drug class type
      • 6.4.2.6.2.Rest of Asia-Pacific Oncology/cancer drugs market, By indication
    • 6.4.3.Asia-Pacific market size and forecast, by drug class type
    • 6.4.4.Asia-Pacific market size and forecast, By indication
  • 6.5.LAMEA
    • 6.5.1.Key market trends, growth factors, and opportunities
    • 6.5.2.Market size and forecast, by country
      • 6.5.2.1.Brazil
      • 6.5.2.1.1.Brazil Oncology/cancer drugs market, by drug class type
      • 6.5.2.1.2.Brazil Oncology/cancer drugs market, By indication
      • 6.5.2.2.Saudi Arabia
      • 6.5.2.2.1.Saudi Arabia Oncology/cancer drugs market, by drug class type
      • 6.5.2.2.2.Saudi Arabia Oncology/cancer drugs market, By indication
      • 6.5.2.3.South Africa
      • 6.5.2.3.1.South Africa Oncology/cancer drugs market, by drug class type
      • 6.5.2.3.2.South Africa Oncology/cancer drugs market, By indication
      • 6.5.2.4.Rest of LAMEA
      • 6.5.2.4.1.Rest of LAMEA Oncology/cancer drugs market, by drug class type
      • 6.5.2.4.2.Rest of LAMEA Oncology/cancer drugs market, By indication
    • 6.5.3.LAMEA market size and forecast, by drug class type
    • 6.5.4.LAMEA market size and forecast, By indication

CHAPTER 7:COMPANY PROFILES

  • 7.1.ABBVIE INC.
    • 7.1.1.Company overview
    • 7.1.2.Company snapshot
    • 7.1.3.Operating business segments
    • 7.1.4.Product portfolio
    • 7.1.5.Business performance
    • 7.1.6.Key strategic moves and developments
  • 7.2.AMGEN, INC.
    • 7.2.1.Company overview
    • 7.2.2.Company snapshot
    • 7.2.3.Operating business segments
    • 7.2.4.Product portfolio
    • 7.2.5.Business performance
    • 7.2.6.Key strategic moves and developments
  • 7.3.ASTELLAS PHARMA INC.
    • 7.3.1.Company overview
    • 7.3.2.Company snapshot
    • 7.3.3.Operating business segments
    • 7.3.4.Product portfolio
    • 7.3.5.Business performance
    • 7.3.6.Key strategic moves and developments
  • 7.4.ASTRAZENECA PLC
    • 7.4.1.Company overview
    • 7.4.2.Company snapshot
    • 7.4.3.Operating business segments
    • 7.4.4.Product portfolio
    • 7.4.5.Business performance
    • 7.4.6.Key strategic moves and developments
  • 7.5.BRISTOL-MYERS SQUIBB COMPANY
    • 7.5.1.Company overview
    • 7.5.2.Company snapshot
    • 7.5.3.Operating business segments
    • 7.5.4.Product Portfolio
    • 7.5.5.Business performance
    • 7.5.6.Key strategic moves and developments
  • 7.6.F. HOFFMANN-LA ROCHE AG
    • 7.6.1.Company overview
    • 7.6.2.Company snapshot
    • 7.6.3.Operating business segments
    • 7.6.4.Product portfolio
    • 7.6.5.Business performance
    • 7.6.6.Key strategic moves and developments
  • 7.7.JOHNSON & JOHNSON
    • 7.7.1.Company overview
    • 7.7.2.Company snapshot
    • 7.7.3.Operating business segments
    • 7.7.4.Product portfolio
    • 7.7.5.Business performance
    • 7.7.6.Key strategic moves and developments
  • 7.8.MERCK & CO., INC.
    • 7.8.1.Company overview
    • 7.8.2.Company snapshot
    • 7.8.3.Operating business segments
    • 7.8.4.Product portfolio
    • 7.8.5.Business performance
    • 7.8.6.Key strategic moves and developments
  • 7.9.NOVARTIS INTERNATIONAL AG
    • 7.9.1.Company overview
    • 7.9.2.Company snapshot
    • 7.9.3.Operating business segments
    • 7.9.4.Product portfolio
    • 7.9.5.Business performance
    • 7.9.6.Key strategic moves and developments
  • 7.10.PFIZER, INC.
    • 7.10.1.Company overview
    • 7.10.2.Company snapshot
    • 7.10.3.Operating business segments
    • 7.10.4.Product portfolio
    • 7.10.5.Business performance
    • 7.10.6.Key strategic moves and development

LIST OF TABLES

  • TABLE 01.COMPLETED CLINICAL TRIALS IN CANCER DRUGS MARKET, 2017-2021
  • TABLE 02.GLOBAL ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2020-2030 ($MILLION)
  • TABLE 03.CHEMOTHERAPY ONCOLOGY/CANCER DRUGS MARKET, BY REGION, 2020-2030 ($MILLION)
  • TABLE 04.TARGETED THERAPY ONCOLOGY/CANCER DRUGS MARKET, BY REGION, 2020-2030 ($MILLION)
  • TABLE 05.IMMUNOTHERAPY ONCOLOGY/CANCER DRUGS MARKET, BY REGION, 2020-2030 ($MILLION)
  • TABLE 06.HORMONAL THERAPY ONCOLOGY/CANCER DRUGS MARKET, BY REGION, 2020-2030 ($MILLION)
  • TABLE 07.ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2020-2030 ($MILLION)
  • TABLE 08.ONCOLOGY/CANCER DRUGS MARKET FOR LUNG CANCER, BY REGION, 2020-2030 ($MILLION)
  • TABLE 09.ONCOLOGY/CANCER DRUGS MARKET FOR STOMACH CANCER, BY REGION, 2020-2030 ($MILLION)
  • TABLE 10.ONCOLOGY/CANCER DRUGS MARKET FOR COLORECTAL CANCER, BY REGION, 2020-2030 ($MILLION)
  • TABLE 11.ONCOLOGY/CANCER DRUGS MARKET FOR BREAST CANCER, BY REGION, 2020-2030 ($MILLION)
  • TABLE 12.ONCOLOGY/CANCER DRUGS MARKET FOR PROSTATE CANCER, BY REGION, 2020-2030 ($MILLION)
  • TABLE 13.ONCOLOGY/CANCER DRUGS MARKET FOR LIVER CANCER, BY REGION, 2020-2030 ($MILLION)
  • TABLE 14.ONCOLOGY/CANCER DRUGS MARKET FOR ESOPHAGEAL CANCER, BY REGION, 2020-2030 ($MILLION)
  • TABLE 15.ONCOLOGY/CANCER DRUGS MARKET FOR CERVICAL CANCER, BY REGION, 2020-2030 ($MILLION)
  • TABLE 16.ONCOLOGY/CANCER DRUGS MARKET FOR KIDNEY CANCER, BY REGION, 2020-2030 ($MILLION)
  • TABLE 17.ONCOLOGY/CANCER DRUGS MARKET FOR BLADDER CANCER, BY REGION, 2020-2030 ($MILLION)
  • TABLE 18.ONCOLOGY/CANCER DRUGS MARKET FOR OTHER CANCER, BY REGION, 2020-2030 ($MILLION)
  • TABLE 19.ONCOLOGY/CANCER DRUGS MARKET, BY REGION, 2020-2030 ($MILLION)
  • TABLE 20.NORTH AMERICA ONCOLOGY/CANCER DRUGS MARKET, BY COUNTRY, 2020-2030 ($MILLION)
  • TABLE 21.U.S. ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2020-2030 ($MILLION)
  • TABLE 22.U.S. ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2020-2030 ($MILLION)
  • TABLE 23.CANADA ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2020-2030 ($MILLION)
  • TABLE 24.CANADA ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2020-2030 ($MILLION)
  • TABLE 25.MEXICO ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2020-2030 ($MILLION)
  • TABLE 26.MEXICO ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2020-2030 ($MILLION)
  • TABLE 27.NORTH AMERICA ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2020-2030 ($MILLION)
  • TABLE 28.NORTH AMERICA ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2020-2030 ($MILLION)
  • TABLE 29.EUROPE ONCOLOGY/CANCER DRUGS MARKET, BY COUNTRY, 2020-2030 ($MILLION)
  • TABLE 30.GERMANY ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2020-2030 ($MILLION)
  • TABLE 31.GERMANY ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2020-2030 ($MILLION)
  • TABLE 32.FRANCE ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2020-2030 ($MILLION)
  • TABLE 33.FRANCE ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2020-2030 ($MILLION)
  • TABLE 34.UK ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2020-2030 ($MILLION)
  • TABLE 35.UK ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2020-2030 ($MILLION)
  • TABLE 36.ITALY ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2020-2030 ($MILLION)
  • TABLE 37.ITALY ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2020-2030 ($MILLION)
  • TABLE 38.SPAIN ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2020-2030 ($MILLION)
  • TABLE 39.SPAIN ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2020-2030 ($MILLION)
  • TABLE 40.REST OF EUROPE ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2020-2030 ($MILLION)
  • TABLE 41.REST OF EUROPE ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2020-2030 ($MILLION)
  • TABLE 42.EUROPE ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2020-2030 ($MILLION)
  • TABLE 43.EUROPE ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2020-2030 ($MILLION)
  • TABLE 44.ASIA-PACIFIC ONCOLOGY/CANCER DRUGS MARKET, BY COUNTRY, 2020-2030 ($MILLION)
  • TABLE 45.JAPAN ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2020-2030 ($MILLION)
  • TABLE 46.JAPAN ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2020-2030 ($MILLION)
  • TABLE 47.CHINA ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2020-2030 ($MILLION)
  • TABLE 48.CHINA ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2020-2030 ($MILLION)
  • TABLE 49.AUSTRALIA ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2020-2030 ($MILLION)
  • TABLE 50.AUSTRALIA ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2020-2030 ($MILLION)
  • TABLE 51.INDIA ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2020-2030 ($MILLION)
  • TABLE 52.INDIA ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2020-2030 ($MILLION)
  • TABLE 53.SOUTH KOREA ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2020-2030 ($MILLION)
  • TABLE 54.SOUTH KOREA ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2020-2030 ($MILLION)
  • TABLE 55.REST OF ASIA-PACIFIC ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2020-2030 ($MILLION)
  • TABLE 56.REST OF ASIA-PACIFIC ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2020-2030 ($MILLION)
  • TABLE 57.ASIA-PACIFIC ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2020-2030 ($MILLION)
  • TABLE 58.ASIA-PACIFIC ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2020-2030 ($MILLION)
  • TABLE 59.LAMEA ONCOLOGY/CANCER DRUGS MARKET, BY COUNTRY, 2020-2030 ($MILLION)
  • TABLE 60.BRAZIL ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2020-2030 ($MILLION)
  • TABLE 61.BRAZIL ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2020-2030 ($MILLION)
  • TABLE 62.SAUDI ARABIA ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2020-2030 ($MILLION)
  • TABLE 63.SAUDI ARABIA ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2020-2030 ($MILLION)
  • TABLE 64.SOUTH AFRICA ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2020-2030 ($MILLION)
  • TABLE 65.SOUTH AFRICA ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2020-2030 ($MILLION)
  • TABLE 66.REST OF LAMEA ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2020-2030 ($MILLION)
  • TABLE 67.REST OF LAMEA ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2020-2030 ($MILLION)
  • TABLE 68.LAMEA ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2020-2030 ($MILLION)
  • TABLE 69.LAMEA ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2020-2030 ($MILLION)
  • TABLE 70.ABBVIE: COMPANY SNAPSHOT
  • TABLE 71.ABBVIE: OPERATING SEGMENTS
  • TABLE 72.ABBVIE: PRODUCT PORTFOLIO
  • TABLE 73.ABBVIE: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 74.AMGEN: COMPANY SNAPSHOT
  • TABLE 75.AMGEN: OPERATING SEGMENTS
  • TABLE 76.AMGEN: PRODUCT PORTFOLIO
  • TABLE 77.AMGEN: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 78.ASTELLAS PHARMA: COMPANY SNAPSHOT
  • TABLE 79.ASTELLAS PHARMA: OERATING SEGMENT
  • TABLE 80.ASTELLAS PHARMA: PRODUCT PORTFOLIO
  • TABLE 81.ASTELLAS PHARMA: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 82.ASTRAZENECA: COMPANY SNAPSHOT
  • TABLE 83.ASTRAZENECA: OPERATING SEGMENTS
  • TABLE 84.ASTRAZENECA: PRODUCT PORTFOLIO
  • TABLE 85.ASTRAZENECA: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 86.BRISTOL-MYERS SQUIBB: COMPANY SNAPSHOT
  • TABLE 87.BRISTOL-MYERS SQUIBB: OPERATING SEGMENTS
  • TABLE 88.BRISTOL-MYERS SQUIBB: PRODUCT PORTFOLIO
  • TABLE 89.ROCHE: COMPANY SNAPSHOT
  • TABLE 90.ROCHE: OPERATING SEGMENTS
  • TABLE 91.ROCHE: PRODUCT PORTFOLIO
  • TABLE 92.ROCHE: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 93.J&J: COMPANY SNAPSHOT
  • TABLE 94.J&J: OPERATING BUSINESS SEGMENTS
  • TABLE 95.J&J: PRODUCT PORTFOLIO
  • TABLE 96.J&J: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 97.MERCK: COMPANY SNAPSHOT
  • TABLE 98.MERCK: OPERATING SEGMENTS
  • TABLE 99.MERCK: PRODUCT PORTFOLIO
  • TABLE 100.MERCK: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 101.NOVARTIS: COMPANY SNAPSHOT
  • TABLE 102.NOVARTIS: OERATING SEGMENT
  • TABLE 103.NOVARTIS: PRODUCT PORTFOLIO
  • TABLE 104.NOVARTIS: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 105.PFIZER: COMPANY SNAPSHOT
  • TABLE 106.PFIZER: OPERATING SEGMENT
  • TABLE 107.PFIZER: PRODUCT TYPE PORTFOLIO
  • TABLE 108.PFIZER: KEY STRATEGIC MOVES AND DEVELOPMENTS

LIST OF FIGURES

  • FIGURE 01.GLOBAL ONCOLOGY/CANCER DRUGS MARKET SEGMENTATION
  • FIGURE 02.TOP INVESTMENT POCKETS
  • FIGURE 03.TOP WINNING STRATEGIES, BY YEAR, 2019-2021
  • FIGURE 04.TOP WINNING STRATEGIES, BY DEVELOPMENT, 2019-2021
  • FIGURE 05.TOP WINNING STRATEGIES, BY COMPANY, 2019-2021
  • FIGURE 06.TOP PLAYER POSITIONING, 2020
  • FIGURE 07.HIGH BARGAINING POWER OF SUPPLIERS
  • FIGURE 08.HIGH BARGAINING POWER OF BUYERS
  • FIGURE 09.MODERATE THREAT OF SUBSTITUTES
  • FIGURE 10.HIGH THREAT OF NEW ENTRANTS
  • FIGURE 11.HIGH INTENSITY OF RIVALRY
  • FIGURE 12.IMPACT ANALYSIS
  • FIGURE 13.COMPARATIVE ANALYSIS OF CHEMOTHERAPY ONCOLOGY/CANCER DRUGS MARKET, BY COUNTRY, 2020 & 2030 ($MILLION)
  • FIGURE 14.COMPARATIVE ANALYSIS OF TARGETED THERAPY ONCOLOGY/CANCER DRUGS MARKET, BY COUNTRY, 2020 & 2030 ($MILLION)
  • FIGURE 15.COMPARATIVE ANALYSIS OF IMMUNOTHERAPY ONCOLOGY/CANCER DRUGS MARKET, BY COUNTRY, 2020 & 2030 ($MILLION)
  • FIGURE 16.COMPARATIVE ANALYSIS OF HORMONAL THERAPY ONCOLOGY/CANCER DRUGS MARKET, BY COUNTRY, 2020 & 2030 ($MILLION)
  • FIGURE 17.COMPARATIVE ANALYSIS OF LUNG CANCER ONCOLOGY/CANCER DRUGS MARKET, BY COUNTRY, 2020-2030 (%)
  • FIGURE 18.COMPARATIVE ANALYSIS OF STOMACH CANCER ONCOLOGY/CANCER DRUGS MARKET, BY COUNTRY, 2020- 2030 (%)
  • FIGURE 19.COMPARATIVE ANALYSIS OF COLORECTAL CANCER ONCOLOGY/CANCER DRUGS MARKET, BY COUNTRY, 2020-2030 (%)
  • FIGURE 20.COMPARATIVE ANALYSIS OF BREAST CANCER ONCOLOGY/CANCER DRUGS MARKET, BY COUNTRY, 2020-2030 (%)
  • FIGURE 21.COMPARATIVE ANALYSIS OF PROSTATE CANCER ONCOLOGY/CANCER DRUGS MARKET, BY COUNTRY, 2020- 2030 (%)
  • FIGURE 22.COMPARATIVE ANALYSIS OF LIVER CANCER ONCOLOGY/CANCER DRUGS MARKET, BY COUNTRY, 2020- 2030 (%)
  • FIGURE 23.COMPARATIVE ANALYSIS OF ESOPHAGEAL CANCER ONCOLOGY/CANCER DRUGS MARKET, BY COUNTRY, 2020- 2030 (%)
  • FIGURE 24.COMPARATIVE ANALYSIS OF CERVICAL CANCER ONCOLOGY/CANCER DRUGS MARKET, BY COUNTRY, 2020- 2030 (%)
  • FIGURE 25.COMPARATIVE ANALYSIS OF KIDNEY CANCER ONCOLOGY/CANCER DRUGS MARKET, BY COUNTRY, 2020- 2030 (%)
  • FIGURE 26.COMPARATIVE ANALYSIS OF BLADDER CANCER ONCOLOGY/CANCER DRUGS MARKET, BY COUNTRY, 2020- 2030 (%)
  • FIGURE 27.COMPARATIVE ANALYSIS OF OTHER CANCER ONCOLOGY/CANCER DRUGS MARKET, BY COUNTRY, 2020- 2030 (%)
  • FIGURE 28.U.S. ONCOLOGY CANCER DRUGS MARKET, 2020-2030 ($MILLION)
  • FIGURE 29.CANADA ONCOLOGY CANCER DRUGS MARKET, 2020-2030 ($MILLION)
  • FIGURE 30.MEXICO ONCOLOGY CANCER DRUGS MARKET, 2020-2030 ($MILLION)
  • FIGURE 31.GERMANY ONCOLOGY CANCER DRUGS MARKET, 2020-2030 ($MILLION)
  • FIGURE 32.FRANCE ONCOLOGY CANCER DRUGS MARKET, 2020-2030 ($MILLION)
  • FIGURE 33.UK ONCOLOGY CANCER DRUGS MARKET, 2020-2030 ($MILLION)
  • FIGURE 34.ITALY ONCOLOGY CANCER DRUGS MARKET, 2020-2030 ($MILLION)
  • FIGURE 35.SPAIN ONCOLOGY CANCER DRUGS MARKET, 2020-2030 ($MILLION)
  • FIGURE 36.REST OF EUROPE ONCOLOGY CANCER DRUGS MARKET, 2020-2030 ($MILLION)
  • FIGURE 37.JAPAN ONCOLOGY CANCER DRUGS MARKET, 2020-2030 ($MILLION)
  • FIGURE 38.CHINA ONCOLOGY CANCER DRUGS MARKET, 2020-2030 ($MILLION)
  • FIGURE 39.AUSTRALIA ONCOLOGY CANCER DRUGS MARKET, 2020-2030 ($MILLION)
  • FIGURE 40.INDIA ONCOLOGY CANCER DRUGS MARKET, 2020-2030 ($MILLION)
  • FIGURE 41.SOUTH KOREA ONCOLOGY CANCER DRUGS MARKET, 2020-2030 ($MILLION)
  • FIGURE 42.REST OF ASIA-PACIFIC ONCOLOGY/CANCER DRUGS MARKET, 2020-2030 ($MILLION)
  • FIGURE 43.BRAZIL ONCOLOGY/CANCER DRUGS MARKET, 2020-2030 ($MILLION)
  • FIGURE 44.SAUDI ARABIA ONCOLOGY/CANCER DRUGS MARKET, 2020-2030 ($MILLION)
  • FIGURE 45.SOUTH AFRICA ONCOLOGY/CANCER DRUGS MARKET, 2020-2030 ($MILLION)
  • FIGURE 46.REST OF LAMEA ONCOLOGY/CANCER DRUGS MARKET, 2020-2030 ($MILLION)
  • FIGURE 47.ABBVIE: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 48.ABBVIE: REVENUE SHARE BY REGION, 2020 (%)
  • FIGURE 49.AMGEN: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 50.AMGEN: REVENUE SHARE BY REGION, 2020 (%)
  • FIGURE 51.ASTELLAS PHARMA: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 52.ASTELLAS PHARMA: REVENUE SHARE BY REGION, 2020 (%)
  • FIGURE 53.ASTRAZENECA: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 54.ASTRAZENECA: REVENUE SHARE BY REGION, 2020 (%)
  • FIGURE 55.BRISTOL-MYERS SQUIBB: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 56.BRISTOL-MYERS SQUIBB: REVENUE SHARE BY REGION, 2020 (%)
  • FIGURE 57.ROCHE: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 58.ROCHE: REVENUE SHARE BY SEGMENT, 2020 (%)
  • FIGURE 59.ROCHE: REVENUE SHARE BY REGION, 2020 (%)
  • FIGURE 60.J&J: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 61.J&J: REVENUE SHARE BY SEGMENT, 2020 (%)
  • FIGURE 62.J&J: REVENUE SHARE BY REGION, 2020(%)
  • FIGURE 63.MERCK: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 64.MERCK: REVENUE SHARE BY SEGMENT, 2020 (%)
  • FIGURE 65.MERCK: REVENUE SHARE BY REGION, 2020 (%)
  • FIGURE 66.NOVARTIS: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 67.NOVARTIS: REVENUE SHARE BY SEGMENT, 2020 (%)
  • FIGURE 68.NOVARTIS: REVENUE SHARE BY REGION, 2020 (%)
  • FIGURE 69.PFIZER: REVENUE, 2018-2020 ($MILLION)
  • FIGURE 70.PFIZER: REVENUE SHARE BY REGION, 2020 (%)